Показать сокращенную информацию
dc.contributor.author | McCurdy S. | |
dc.contributor.author | Liu C. | |
dc.contributor.author | Yap J. | |
dc.contributor.author | Boisvert W. | |
dc.date.accessioned | 2018-04-05T07:09:30Z | |
dc.date.available | 2018-04-05T07:09:30Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1043-4666 | |
dc.identifier.uri | http://dspace.kpfu.ru/xmlui/handle/net/129778 | |
dc.description.abstract | © 2017 Elsevier Ltd. IL-37 is a member of the IL-1 family, but unlike most other members of this family of cytokines, it has wide-ranging anti-inflammatory properties. Initially shown to bind IL-18 binding protein and prevent IL-18-mediated inflammation, its known role has been expanded to include distinct pathways, both intracellular involving the transcription factor Smad3, and extracellular via binding to the orphan receptor IL-1R8. A number of recent publications investigating the role of IL-37 in atherosclerosis and ischemic heart disease have revealed promising therapeutic value of the cytokine. Although research concerning the role of IL-37 and its mechanism in atherosclerosis is relatively scant, there are a number of well-known atherosclerotic processes that this cytokine can mediate with the potential of modulating the disease progression itself. This review will probe in detail the effects of IL-37 on important pathological processes such as inflammation, dysregulated lipid metabolism, and apoptosis, by analyzing existing data as well as exploring the potential of this cytokine to influence these properties. | |
dc.relation.ispartofseries | Cytokine | |
dc.subject | Anti-inflammatory properties | |
dc.subject | Atherosclerosis | |
dc.subject | IL-37 | |
dc.title | Potential role of IL-37 in atherosclerosis | |
dc.type | Article in Press | |
dc.collection | Публикации сотрудников КФУ | |
dc.source.id | SCOPUS10434666-2017-SID85030552867 |